Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DYIA63
|
|||
| Drug Name |
CVM-1118
|
|||
| Synonyms |
Foslinanib; UNII-2X2DNM7NGX; 5-yl dihydrogen phosphate; 2X2DNM7NGX; 1256037-60-1; 2-(3-fluorophenyl)-6-methoxy-4-oxo-1,4-dihydroquinolin-; 2-(3-Fluorophenyl)-6-methoxy-4-oxo-1,4-dihydroquinolin-5-yl dihydrogen phosphate; Foslinanib [INN]; Foslinanib [USAN]; Foslinanib (USAN/INN); Foslinanib [USAN:INN]; TRX-818 FREE ACID; SCHEMBL339272; CVM-1118 FREE ACID; CHEMBL1615993; TRX 818; WHO 10721; D11639; 4(1H)-Quinolinone, 2-(3-fluorophenyl)-6-methoxy-5-(phosphonooxy)-; 2-(3-Fluorophenyl)-4-hydroxy-6-methoxyquinolin-5-yl dihydrogen phosphate; 2054938-73-5
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Neuroendocrine cancer [ICD-11: 2B72.1; ICD-9: 209] | Phase 2 | [1] | |
| Company |
TaiRx
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H13FNO6P
|
|||
| Canonical SMILES |
COC1=C(C2=C(C=C1)NC(=CC2=O)C3=CC(=CC=C3)F)OP(=O)(O)O
|
|||
| InChI |
1S/C16H13FNO6P/c1-23-14-6-5-11-15(16(14)24-25(20,21)22)13(19)8-12(18-11)9-3-2-4-10(17)7-9/h2-8H,1H3,(H,18,19)(H2,20,21,22)
|
|||
| InChIKey |
ZDWFMAHQGDEALT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1256037-60-1
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03600233) Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.